PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Hidradenitis

Drugs in development · updated 30 October 2026

Hidradenitis: drugs in development

As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for hidradenitis. 7 are experimental, that is not yet approved in the United States.

12Active trials
7Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
PovorcitinibPovofortay®III3NCT06855498
SonelokimabIII2NCT07007637
DuvakitugII1NCT07812116
LAD328II1NCT07547813
SPY072II1NCT07766005
TibulizumabII1NCT06993610
SAR447971I1NCT07629336

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
RemibrutinibLOU064, Rhapsido®III2NCT06840392
BimekizumabBimzelx®II1NCT07766005

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016575 “Hidradenitis”.

ItalianoFrançaisDeutsch